title: Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
abstract: BACKGROUND
  Trials of transfusions of platelets (PLTs) treated with amotosalen-based pathogen reduction (PR) showed lower corrected count increments (CCIs) compared to conventional PLT components (PCs). However, PR-PLTs and conventional PCs often differed in various factors besides PR. We compared transfusion efficacy of single-donor apheresis PCs treated with PR or gamma irradiation.
  
  
  METHODS
  Hematologic patients were assigned to receive PR-PLTs or gamma-irradiated conventional PCs, both prepared in PLT additive solution (PAS). One-hour CCI (primary endpoint), 24-hour CCI, time to next PLT transfusion, and transfusion requirement of red blood cells and plasma were analyzed.
  
  
  RESULTS
  Forty-four patients assigned to PR-PLTs received 220 PR-PLTs and 136 conventional PCs; 72 controls received 517 conventional PCs. No differences between patient groups were observed for mean (±standard deviation [SD]) 1-hour CCI (11.4 [±4.9] for PR-PLT vs. 11.0 [±4.9] for controls), mean (±SD) 24-hour CCI (6.1 [±4.4] for PR-PLTs vs. 6.2 [±4.8] for controls), and for the other evaluated outcomes. No differences between PC types were observed for mean (±SD) 1-hour CCI (10.6 [±6.7] for PR-PLTs vs. 9.9 [±6.2] for conventional PCs) and mean 24 hour-CCI (3.3 [±3.9] for PR-PLTs vs. 4.2 [±5] for conventional PCs). Thirty-five percent of PR-PLTs and 38% of conventional PCs (p = 0.63) were associated with 1-hour CCIs of less than 7.5. Inadequate 24-hour CCIs were observed for 72% of PR-PLTs and 64% of conventional PCs (p = 0.002).
  
  
  CONCLUSIONS
  Transfusion efficacy of single-donor apheresis PCs in PAS treated with amotosalen PR versus gamma irradiation is comparable.
authors.affiliation: Blood Transfusion Center Swiss Red Cross, Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Joerg-Peter
authors.initials: JP
authors.lastname: Sigle
authors.forename: Laura
authors.initials: L
authors.lastname: Infanti
authors.forename: Jan-Dirk
authors.initials: JD
authors.lastname: Studt
authors.forename: Maria
authors.initials: M
authors.lastname: Martinez
authors.forename: Martin
authors.initials: M
authors.lastname: Stern
authors.forename: Alois
authors.initials: A
authors.lastname: Gratwohl
authors.forename: Jakob
authors.initials: J
authors.lastname: Passweg
authors.forename: André
authors.initials: A
authors.lastname: Tichelli
authors.forename: Andreas S
authors.initials: AS
authors.lastname: Buser
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets / Q000187:drug effects / Q000528:radiation effects; D058731:Blood Safety / Q000009:adverse effects / Q000379:methods*; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data; D005260:Female; D011564:Furocoumarins / Q000009:adverse effects*; D005720:Gamma Rays / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D017319:Photosensitizing Agents / Q000009:adverse effects*; D010949:Plasma; D010976:Platelet Count; D017713:Platelet Transfusion / Q000706:statistics & numerical data; D011446:Prospective Studies
chemical_list: D011564:Furocoumarins; D017319:Photosensitizing Agents; C118577:amotosalen